explore -WSS

explore

author：explore 2025-09-29 23:04:32 - browse：79

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Feds fine Medicare Advantage plans for overcharging members

WSS

2024 GOP presidential candidates spar over abortion in debate

Diversity in medical illustrations gets boost from Chidiebere Ibe

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Feds fine Medicare Advantage plans for overcharging members

AstraZeneca challenges Medicare drug negotiation program

My chronic pain journey would have been easier knowing 5 things % STAT

focus

explore

explore

As demand for Covid shots wanes, Moderna seeks its next success

Psilocybin's anti

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Clinic falsely told dozens they had Alzheimer's, suits say

What does generative AI mean for health care? We asked experts

Inside the culture of fear in the White House science office of Eric Lander

Wildfire smoke exposes gaps in outdoor worker protections

Diversity in medical illustrations gets boost from Chidiebere Ibe

After affirmative action ruling, medical educators look to 'holistic review'

Mike Pence ‘not interested in trading insults’ with Trump as he tries to win New Hampshire

hotspot

Clinic falsely told dozens they had Alzheimer's, suits say

AstraZeneca bets AAV gene therapy will still deliver the goods

What Henrietta Lacks's story taught me about my role as a doctor

FDA panel gives mixed vote on blood pressure devices

Doctors have an ethical obligation to be advocates

Study finds new variant for Parkinson’s in African populations

focus

focus

leisure time

explore